U.S. Markets close in 6 hrs 23 mins

Simulations Plus Releases ADMET Predictor™ Version 8.5


Simulations Plus, Inc. (SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, chemicals, and consumer goods industries, today announced that it has released version 8.5 of its best-in-class molecular property prediction program, ADMET Predictor™.

Dr. David Miller, director of ADMET Cheminformatics, said: “Working with our colleagues in the Simulation Sciences department, we have merged the mechanistic oral absorption (ACAT™) and minimal PBPK models from GastroPlus™ into this new version of ADMET Predictor to create the High Throughput Pharmacokinetics (HTPK) Simulation Module. This capability now allows chemists to seamlessly combine our top-rated QSAR models with virtual rat and human physiology models to drive lead selection and optimization activities. This novel approach, which we are terming ‘discovery PBPK,’ should lead to more efficient screening of candidate molecules in early discovery and improve communication between chemists and DMPK scientists as compounds progress into early development. Other key improvements in this version of ADMET Predictor include:

  • New synthetic difficulty scores to guide strategic resource allocation during drug design
  • Improved Ames mutagenicity models – a key toxicity endpoint required for all drug applications
  • Optimization of spreadsheet and model-building functions to improve speed and efficiency
  • Enhanced command-line capabilities to streamline all major program operations.”

John DiBella, president of the Lancaster division for Simulations Plus, added: “We collaborated with a large pharmaceutical company over several years to implement this new ‘discovery PBPK’ approach using the standalone GastroPlus and ADMET Predictor programs, submitting several manuscripts for publication in the process. We always had a goal in mind to integrate this capability into an easy-to-use application, and we have now successfully done so. The initial reception has been extremely positive, and we have received many requests for evaluation. We expect the new HTPK Simulation Module, as an optional add-on license, and the other exciting new features in version 8.5 to further the solid sales gains ADMET Predictor has realized over the past five years as more chemistry and DMPK departments adopt our unique solutions.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171130005304/en/